Work

Incidence rate and prevalence of idiopathic pulmonary fibrosis in the United States 2017-2022

Year: 2025

Type: article

Abstract: RATIONALE: Idiopathic pulmonary fibrosis (IPF) is an incurable chronic progressive fibrotic lung disease with median survival of 3-5 years from diagnosis. Estimates of incidence rate and prevalence of IPF are outdated and vary widely due to differences in study methodology and diagnostic definitions. OBJECTIVES: To provide an up-to-date estimate of IPF incidence rates and prevalence and describe the comorbidity burden for people with IPF in the United States. METHODS: This non-interventional retrospective study used claims data from the Optum Clinformatics Data Mart database from 2017 to 2022. Individuals were required to have at least 365-day continuous enrollment in the database to enter the study. Individuals with IPF were identified based on claims with the International Classification of Diseases, Tenth Revision code for IPF (J84.112) following study entry. IPF definitions varied by requirement for 1 or 2 qualifying IPF claims and computed tomography scan of the chest and/or lung biopsy. In this analysis, 3 primary case definitions and 2 sensitivity analysis definitions were used to identify individuals with IPF. RESULTS: By primary case definitions, the overall crude and age- and sex-adjusted incidence rates (per 100,000 person-years) were 14.5-26.1 and 9.8-18.4, respectively; the crude and adjusted prevalences (per 100,000 persons) were 46.3-88.9 and 34.4-67.1, respectively. Incidence rate and prevalence increased markedly with age and varied with ethnicity and region. The most frequent comorbidities were systemic hypertension, chronic obstructive pulmonary disease, and coronary artery disease. CONCLUSIONS: This study provides an up-to-date summary of the incidence rate and prevalence of IPF in the United States and shows a substantial burden of comorbidities among patients diagnosed with IPF.

Source: Annals of the American Thoracic Society

DOI: 10.1513/annalsats.202503-262oc

Authors: Yanni Fan, Haikun Bao, Pratik Pimple, Amy L Olson, Steven D Nathan

Institutions: Boehringer Ingelheim (United States), Inova Fairfax Hospital

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: Boehringer Ingelheim